Search research articles
Contact Us
Filters
Showing results (151-160 of 357) with videos related to
Page
of 36
Sort By:
The New England Journal of Medicine
|
June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain, Karim Fizazi, Fred Saad, et al.
The Oncologist
|
June 17, 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations
Mark C Markowski, Cora N Sternberg, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
European Urology
|
April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
Urology
|
February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
Cora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Cancer
|
June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study
David J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Cancer
|
March 26, 2003
Can patient selection for bladder preservation be based on response to chemotherapy?
Cora N Sternberg, Vito Pansadoro, Fabio Calabrò, et al.
Frontiers in Oncology
|
November 29, 2012
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
Eugenio Donato Di Paola, Silvia Alonso, Rosa Giuliani, et al.
BJU International
|
January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment
Andrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
Future Oncology (London, England)
|
August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Page
of 36
Search research articles
Search
Showing results (151-160 of 357) with videos related to
Sort By:
Page
of 36
The New England Journal of Medicine
|
June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain, Karim Fizazi, Fred Saad, et al.
The Oncologist
|
June 17, 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations
Mark C Markowski, Cora N Sternberg, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
European Urology
|
April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
Urology
|
February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
Cora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Cancer
|
June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study
David J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Cancer
|
March 26, 2003
Can patient selection for bladder preservation be based on response to chemotherapy?
Cora N Sternberg, Vito Pansadoro, Fabio Calabrò, et al.
Frontiers in Oncology
|
November 29, 2012
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
Eugenio Donato Di Paola, Silvia Alonso, Rosa Giuliani, et al.
BJU International
|
January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment
Andrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
Future Oncology (London, England)
|
August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Page
of 36